Myriad Genetics (MYGN) announced the full commercial launch of FirstGene Multiple Prenatal Screen, a laboratory test that performs four prenatal genetic screens from a single maternal blood draw, designed to be done early in pregnancy. The update is product-focused with no reported financial figures, but it modestly improves its diagnostics offering and revenue opportunity outlook.
Myriad Genetics (MYGN) announced the full commercial launch of FirstGene Multiple Prenatal Screen, a laboratory test that performs four prenatal genetic screens from a single maternal blood draw, designed to be done early in pregnancy. The update is product-focused with no reported financial figures, but it modestly improves its diagnostics offering and revenue opportunity outlook.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
mildly positive
Sentiment Score
0.12
Ticker Sentiment
